Overview

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
SyneuRx International (Taiwan) Corp
Treatments:
Sodium Benzoate